WO2009136763A3 - Nanoparticles for penetration of blood-brain barrier - Google Patents

Nanoparticles for penetration of blood-brain barrier Download PDF

Info

Publication number
WO2009136763A3
WO2009136763A3 PCT/KR2009/002440 KR2009002440W WO2009136763A3 WO 2009136763 A3 WO2009136763 A3 WO 2009136763A3 KR 2009002440 W KR2009002440 W KR 2009002440W WO 2009136763 A3 WO2009136763 A3 WO 2009136763A3
Authority
WO
WIPO (PCT)
Prior art keywords
brain
blood
nanoparticle
brain barrier
penetration
Prior art date
Application number
PCT/KR2009/002440
Other languages
French (fr)
Other versions
WO2009136763A2 (en
Inventor
Jin Woo Cheon
Jae-Hyun Lee
Original Assignee
Industry-Academic Cooperation Foundation, Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry-Academic Cooperation Foundation, Yonsei University filed Critical Industry-Academic Cooperation Foundation, Yonsei University
Publication of WO2009136763A2 publication Critical patent/WO2009136763A2/en
Publication of WO2009136763A3 publication Critical patent/WO2009136763A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A61K49/1869—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid coated or functionalised with a protein being an albumin, e.g. HSA, BSA, ovalbumin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates to (a) a nanoparticle for penetration of a blood-brain barrier (BBB) comprising an inorganic nanoparticle core and a water-soluble multi-functional organic ligand coated on the nanoparticle core, and (b) a composition for brain imaging and (c) a pharmaceutical composition for brain-targeting thereof. The basic strategy adopted in the present invention is based on the finding that the water-soluble multi-functional organic ligand coated on the nanoparticle core permits the nanoparticle to penetrate the blood-brain barrier. The nanoparticle of the present invention may be efficiently used as a brain-imaging agent and in a drug delivery system into brain since the inorganic nanoparticle core coated with the water-soluble multi-functional organic ligand ensures an effective penetration of the blood-brain barrier even with no use of conventional adjuvants.
PCT/KR2009/002440 2008-05-09 2009-05-08 Nanoparticles for penetration of blood-brain barrier WO2009136763A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080043666 2008-05-09
KR10-2008-0043666 2008-05-09

Publications (2)

Publication Number Publication Date
WO2009136763A2 WO2009136763A2 (en) 2009-11-12
WO2009136763A3 true WO2009136763A3 (en) 2010-02-11

Family

ID=41265181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002440 WO2009136763A2 (en) 2008-05-09 2009-05-08 Nanoparticles for penetration of blood-brain barrier

Country Status (2)

Country Link
KR (1) KR101081445B1 (en)
WO (1) WO2009136763A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5755732B2 (en) * 2010-06-10 2015-07-29 ミダテック リミテッド Peptide-supported nanoparticles
KR101233439B1 (en) * 2010-07-29 2013-02-14 연세대학교 산학협력단 Stimuli sensitive magnetic nanocomposites using pyrene conjugated polymer and contrast compositions
KR101805873B1 (en) * 2011-08-03 2018-01-10 한화케미칼 주식회사 A nanoparticles of surface-modified with monosaccharide phosphate or monosaccharide phosphate derivatives, its colloidal solution and use thereof
US10307372B2 (en) * 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US20130315834A1 (en) * 2010-09-24 2013-11-28 Nagamani Praveen Nanoprobe comprising gold colloid nanoparticles for multimodality optical imaging of cancer and targeted drug delivery for cancer
WO2012050810A2 (en) 2010-09-29 2012-04-19 The Board Of Trustees Of The University Of Alabama Shape-controlled magnetic nanoparticles as t1 contrast agents for magnetic resonance imaging
RU2475233C2 (en) * 2010-12-01 2013-02-20 Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН Pharmacological composition for intranasal introduction for cerebral delivery of pharmacologically active component, and method for preparing it
EP2675486A2 (en) 2011-02-15 2013-12-25 Semmelweis Egyetem Prussian blue based nanoparticle as multimodal imaging contrast material
US20150369794A1 (en) * 2014-06-18 2015-12-24 Ruprecht Keller Method for Identifying of a Biological Sample of a Mammal, Composition for use in this method and Kit for Performance of this Method
CN107297511B (en) * 2016-04-15 2019-04-23 中国科学院苏州纳米技术与纳米仿生研究所 The method of dynamic reversible regulation surface plasma body resonant vibration property
KR102171656B1 (en) * 2018-12-26 2020-10-29 전북대학교산학협력단 Method for producing transition metal-ferrite bionanocomposite
WO2021001043A1 (en) 2019-07-04 2021-01-07 Monika Wetzke Location-independent intake control
WO2022067430A1 (en) * 2020-09-30 2022-04-07 The Governing Council Of The University Of Toronto Blood-brain barrier-penetrating nanotheranostics for acute and chronic neurodegenerative diseases and the like
CN112326630B (en) * 2021-01-04 2021-03-16 中国工程物理研究院激光聚变研究中心 SERS chip for novel coronavirus detection and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010013745A (en) * 1999-12-13 2001-02-26 메디노바 메디칼 컨설팅 지엠비에이치 Drug targeting system, method of its preparation and its use
US6333110B1 (en) * 1998-11-10 2001-12-25 Bio-Pixels Ltd. Functionalized nanocrystals as visual tissue-specific imaging agents, and methods for fluorescence imaging
US20060073210A1 (en) * 2004-10-05 2006-04-06 Hsing-Wen Sung Nanoparticles for paracellular drug delivery
KR20060098213A (en) * 2005-03-11 2006-09-18 학교법인연세대학교 Nanohybrid particles for diagnosis and treatment of tumor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333110B1 (en) * 1998-11-10 2001-12-25 Bio-Pixels Ltd. Functionalized nanocrystals as visual tissue-specific imaging agents, and methods for fluorescence imaging
KR20010013745A (en) * 1999-12-13 2001-02-26 메디노바 메디칼 컨설팅 지엠비에이치 Drug targeting system, method of its preparation and its use
US20060073210A1 (en) * 2004-10-05 2006-04-06 Hsing-Wen Sung Nanoparticles for paracellular drug delivery
KR20060098213A (en) * 2005-03-11 2006-09-18 학교법인연세대학교 Nanohybrid particles for diagnosis and treatment of tumor

Also Published As

Publication number Publication date
KR101081445B1 (en) 2011-11-08
WO2009136763A2 (en) 2009-11-12
KR20090117648A (en) 2009-11-12

Similar Documents

Publication Publication Date Title
WO2009136763A3 (en) Nanoparticles for penetration of blood-brain barrier
WO2006108405A3 (en) Nanoparticle/active ingredient conjugate
WO2014121235A3 (en) Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
JP2008535927A5 (en)
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
WO2010128504A3 (en) Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery
WO2008011194A3 (en) Transmucosal delivery devices with enhanced uptake
EP2559434A3 (en) Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist
WO2009110984A3 (en) Contrast agents for applications including perfusion imaging
EP2366339A3 (en) Compound barb medical device and method
WO2010025931A3 (en) Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2 -methyl-propyl) - phenol and an antiepileptic
BRPI1014139A2 (en) drug delivery system comprising polyoxazoline and a biotive agent.
EP2481409A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
BRPI0914192A2 (en) transdermal drug delivery using an osmolyte and vasoactive agent
WO2012101639A3 (en) Nanoparticles based for dermal and systemic delivery of drugs
WO2010096733A3 (en) Luminescent porous silicon nanoparticles, methods of making and using same
ECSP13012534A (en) PHARMACEUTICAL COMPOSITION
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
WO2010072958A3 (en) Topical pharmaceutical composition containing a water-sensitive active principle
WO2010021607A3 (en) Pharmaceutical formulation
WO2014130866A3 (en) Targeted buccal delivery comprising cisplatin-loaded chitosan nanoparticles
JP2016539921A5 (en)
WO2014060638A8 (en) A veterinary method of alleviating noise aversion
WO2015038552A3 (en) Aspirin formulation for increased efficacy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09742869

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09742869

Country of ref document: EP

Kind code of ref document: A2